To make an appointment, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment online
As a leader in cancer research, Karmanos is able to offer patients access to innovative treatments and clinical trials that are often times not available anywhere else.
To offer hope and longer life to patients with all types of cancer, Karmanos offers the latest types of therapy through our clinical trials program. Through clinical trials, we are creating new knowledge about how therapies fight cancer and provide national leadership in testing these new therapies.
We understand that cancer is a complex disease that demands complex care. We provide each patient with a dynamic, carefully constructed treatment plan focused on their specific cancer and their unique needs.
We listen to you to design a plan that provides you with respect, compassionate care and is responsive to your emotional and practical concerns.
The Population Studies and Disparities Research (PSDR) Program is committed to identifying key genetic and behavioral risk factors underlying disease onset and progression, and developing and testing novel intervention strategies to reduce risk and improve diagnosis, treatment and outcomes with an emphasis on reducing and/or eliminating cancer health disparities among populations contained within our catchment area.
The PSDR Program themes encompass research to reduce and eliminate disparities across the cancer experience of adult and pediatric populations, and include a diversity of race/ethnic groups.
Members of the Population Studies & Disparities Research Program regularly interact in several ways to develop scientific directions and implement strategic planning efforts including:
The metropolitan Detroit area is home to a highly diverse and medically underserved population. As part of the original SEER program of nine registries dating back to 1973, we contribute approximately 38% of the national cancer incidence and survival data for African Americans. The SEER registry is not only used for descriptive studies; it provides a population-based source of cases for case-control and case-case comparisons. There are ~25,000 new cancers diagnosed in Metropolitan Detroit each year, with about 25% of those being diagnosed in African Americans. In addition to the large African American population, this area is home to the largest concentration of Arab Americans in the United States. This population diversity provides a remarkable opportunity for the study of race/ethnicity related health disparities. All of the research described is conducted in this context and includes substantial numbers of minorities.
Program Leader, Population Studies and Disparities Research Program Director, Epidemiology Research Core Barbara Ann Karmanos Cancer Institute Professor, Department of Oncology Wayne State University School of Medicine dimmerj@wayne.edu
Co-Program Leader, Population Studies and Disparities Research Barbara Ann Karmanos Cancer Institute Associate Professor, Department of Oncology Wayne State University School of Medicine lauren.hamel@wayne.med.edu
Hayley Thompson, Ph.D., associate center director of Community Outreach and Engagement, faculty supervisor of the Office of Community Outreac...
Patient Power Often, Hodgkin lymphoma patients experience skin changes, whether it is a side effect from treatment or a symptom from the cancer.&n...
The Utilization Review Accreditation Commission (URAC) has again awarded KSP , McLaren’s Specialty Pharmacy, as a 2024 Specialty Pharmacy Pioneer ...